Heart Test Safe for Global Use
A blood test that spots whether people are at risk of a heart attack could improve the treatment of people with chest pain at emergency departments around the world, a study suggests.
The test can accurately rule out the risk of heart attack in almost half of all people arriving at hospital emergency departments with chest pains, a worldwide study has found.
Use of the test on arrival at hospital could save millions of patients from undergoing further tests and potentially reduce healthcare costs, the researchers say.
Experts are calling for international guidelines for the treatment of chest pain to be updated so that the test can be integrated into standard care.
"We believe the findings of this worldwide study will provide national and international guidelines committees with the evidence they need to recommend the use of troponin testing to rule out heart attacks much earlier in the emergency department."
Dr Andrew Chapman, British Heart Foundation Research Fellow, University of Edinburgh
The test measures levels of a protein called troponin – which is released by damaged heart cells – in patients’ blood.
The higher the level of troponin in the blood, the more likely it is that a person has had – or is likely to have – a heart attack.
In early studies, the test accurately predicted the risk of heart attack in more than 6000 patients admitted to hospital in Scotland.
The latest research, led by the University of Edinburgh, involved almost 23,000 people at 19 hospitals across Europe, North America and Australasia, who received the test after arriving with chest pains.
The findings pinpointed a threshold level of troponin in the blood, below which patients are unlikely to have had a heart attack and are at very low risk of experiencing one in the next 30 days.
Results from the test – which costs around £5 per patient – can be obtained in as little as 20 minutes, helping to safely rule out a heart attack within an hour of arrival at hospital.
Chest pain is a common reason for people to present at emergency departments but fewer than one in five of those patients are actually having a heart attack.
In the UK, people with chest pain are already given the troponin test when they arrive in emergency departments.
Under current guidelines for interpreting the results, however, most patients fall into a high risk category that requires them to be admitted to hospital for observation and repeated troponin tests.
Experts say their findings confirm that the guidelines can be safely revised, which could dramatically improve healthcare efficiency by enabling doctors to discharge patients not at risk after the results of the first test.
The research, published today in the Journal of the American Medical Association, is being presented at the American Heart Association Scientific Sessions.
This article has been republished from materials provided by The University of Edinburgh. Note: material may have been edited for length and content. For further information, please contact the cited source.
Chapman, A. R., Lee, K. K., Mcallister, D. A., Cullen, L., Greenslade, J. H., Parsonage, W., . . . Mills, N. L. (2017). Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. Jama. doi:10.1001/jama.2017.17488
Dipstick Technology Enables Rapid Diagnosis AnywhereNews
A new Australian study has reported a revolutionary dipstick technology that allows DNA and RNA to be extracted from living organisms in as little as 30 seconds.READ MORE
Molecules in Spit Could Help Diagnose ConcussionsNews
Diagnosing a concussion can sometimes be a guessing game, but clues taken from small molecules in saliva may be able to help diagnose and predict the duration of concussions in children, according to Penn State College of Medicine researchers.READ MORE
Breakthrough Discovery In Diagnostic Tools That Can Replace AntibodiesNews
Experts from the University of Leicester have announced the development of polymeric materials with molecular recognition capabilities which hold the potential to outperform natural antibodies in various diagnostic applications.READ MORE